Answers are grounded in this paper and cite their sources.
A significant proportion of people living with HIV on rivaroxaban are concomitantly prescribed interacting antiretroviral therapies, highlighting the need for careful DOAC selection and monitoring.
DOAC use increased substantially in PWH by 2016. Although rivaroxaban is not recommended with RTV or COBI, concomitant use was recorded in 41% of rivaroxaban recipients in this cohort. As DOAC usage increases, clinicians need to be aware of potential DOAC/ARV interactions in order to select the most appropriate oral anticoagulant and monitoring plan for PWH.
No takes yet. Share an insight, caveat, or question.
George et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: